【环球网报道 记者 李梓瑜】据美国《国会山报》报道，美国总统特朗普当地时间15日在白宫椭圆形办公室称，美国政府正"考虑"对大麻进行重新分 类，将其列为"危害性较低的毒品"。 此前，《华盛顿邮报》等媒体11日援引知情人士消息称，美国政府预计将推动联邦层面大幅放宽对大麻的管制，将对大麻及其衍生物的监管力度降至 与部分常见处方止痛药及其他药物相同的水平。特朗普10日在椭圆形办公室与美国共和党籍众议院议长迈克·约翰逊通话时讨论了这一计划，并预计通 过即将签署的行政令，要求联邦机构重新对大麻进行分类，从而放宽其获取限制。知情人士透露，约翰逊对此持怀疑态度，他列举多项研究及数据反 对重新对大麻进行分类。报道说，"此举不会使大麻合法化或去刑事犯罪化，但将降低相关研究门槛，并提高企业合法经营底线"。 据了解，大麻具有成瘾性，是联合国禁毒公约中被管制的麻醉药品。研究显示，使用大麻会影响人身心健康，长期大剂量使用可引起退行性变化的脑 疾病、严重的行为损伤、免疫系统抑制和神经疾病等。 然而，随着医用大麻以及非医用大麻在美国多州多地陆续放开，在联邦层面推进大麻合法化或去刑事犯罪化的运动悄然兴起。近来，美国大麻合法化 成蔓延之势，与利 ...

Tilray's stock, and shares of other cannabis companies, soared after reports provided investors hope that President Trump would move to have marijuana reclassified as a much less dangerous drug than i... ...

【环球网报道 记者 张倩】据美国《华盛顿邮报》和《福布斯》杂志网站11日报道，知情人士透露，美国政府预计将推动联邦层面大幅 放宽对大麻的管制，将大麻及其衍生物的监管力度降至与部分常见处方止痛药及其他药物相同的水平。 《华盛顿邮报》援引知情人士消息称，美国总统特朗普10日在白宫椭圆形办公室与美国共和党籍众议院议长迈克·约翰逊通话时讨论了 这一计划。卫生与公共服务部长小罗伯特·肯尼迪、医疗保险和医疗补助服务中心主任穆罕默德·奥兹以及大麻相关行业高管也参与了通 话。知情人士称，特朗普预计将通过即将签署的行政令，要求联邦机构重新对大麻进行分类，从而放宽其获取限制。 报道称，知情人士同时表示，约翰逊对此持怀疑态度，他列举多项研究及数据反对重新对大麻进行分类。特朗普随后将电话转交给围 坐在他办公桌旁的行业高管们，由他们反驳约翰逊的论点。 然而，随着医用大麻以及非医用大麻在美国多州多地陆续放开，在联邦层面推进大麻合法化或去刑事犯罪化的运动悄然兴起。近来， 美国大麻合法化成蔓延之势，与利益集团利用金钱政治进行钱权交易密不可分。据美国"公开的秘密"网站统计数据显示，从2018年到 2022年，与大麻产品相关的美国企业和行业协会 ...

The company opened the doors of a new dispensary, while lawmakers in Congress submitted a new pot reform resolution.Marijuana company Curaleaf (CURLF +9.02%) is expanding its presence in a potentially massive market, a move that resonated with investors on Thursday. That, plus a new weed reform resolution filed in the U.S. Congress, helped push the multi-state operator's (MSO) stock price up by 9% that trading session. Making hay while the sun shinesAfter market close Wednesday, Curaleaf announced it had op ...

With Congress passing the funding bill on Wednesday, ending the record-long government shutdown, a controversial provision has made its way into the bill’s provisions, one that is sparking alarm across the hemp and cannabis industry. Move To Re-Criminalize Hemp-Derived ProductsA last-minute provision in the funding package that the Senate passed on Monday comes with a surprise catch: the criminalization of several THC-infused and hemp-derived products across the country, which were legalized as part of the ...

Core Insights - The marijuana industry is experiencing volatility, with potential for improved trading levels driven by legal reforms and earnings reports [1][2][3] Industry Overview - There is ongoing speculation regarding the legalization or rescheduling of cannabis, which influences trading dynamics [2] - The push for more legal states and the end of cannabis prohibition in the U.S. has positively impacted marijuana stocks over the past five years [1] Company Highlights - **WM Technology, Inc.**: An online cannabis marketplace that provides e-commerce and compliance software solutions. The company is set to release its Q3 2025 results on November 6, 2025 [4] - **Hydrofarm Holdings Group, Inc.**: Manufactures and distributes hydroponics equipment for controlled environment agriculture in the U.S. and Canada. Recently, the company made changes to its board of directors [5][7] - **GrowGeneration Corp.**: Operates retail hydroponic and organic gardening stores in the U.S. The company recently launched a new product aimed at improving cannabis flower development [8][10] Investment Opportunities - Companies like WM Technology, Hydrofarm, and GrowGeneration are identified as potential stocks to watch for better trading outcomes, especially as they prepare to report earnings [3][6]

Core Insights - Marijuana Exchange-Traded Funds (ETFs) have seen a significant resurgence, with some increasing over 100% in the past three months after a poor performance in 2024, driven by the U.S. administration's push for marijuana legalization [1][4] Market Performance - The cannabis market faced heavy losses in 2024 due to regulatory challenges and high tax burdens under IRS code 280E, despite a strong demand trend [2] - Market oversupply and competition from lower-priced illicit products led to disappointing quarterly results, causing major ETFs like AdvisorShares Pure US Cannabis ETF (MSOS) and Amplify Seymour Cannabis ETF (CNBS) to decline over 45% last year [3] Regulatory Changes - A shift in outlook began in July 2025 when news surfaced about the potential rescheduling of cannabis from Schedule I to Schedule III, which could ease tax burdens and promote scientific research [4] - Recent political support from President Trump for marijuana legalization has further fueled investor optimism regarding federal cannabis policy changes [4] ETF Performance - **AdvisorShares Pure US Cannabis ETF (MSOS)**: Experienced a 45.6% loss in 2024 but surged 114.5% in the past three months, with top holdings including Curaleaf Holdings (24.01%), Trulieve Cannabis (22.17%), and Green Thumb Industries (20.68%) [6] - **Amplify Seymour Cannabis ETF (CNBS)**: Plummeted 52% in 2024 but rebounded with a 102.1% increase in the last three months, holding Trulieve Cannabis (16.07%), Green Thumb Industries (14.06%), and Curaleaf Holdings (12.31%) [7] - **Roundhill Cannabis ETF (WEED)**: Declined 44.9% in 2024 but surged 120.2% recently, with top holdings including Curaleaf Holdings (28.85%), Green Thumb Industries (28.18%), and Trulieve Cannabis (25.54%) [8] - **Amplify Alternative Harvest ETF (MJ)**: Fell 30.7% in 2024 but increased by 96.3% in the past three months, with major holdings in Amplify Seymour Cannabis ETF (49.30%) and Tilray Brands (21.11%) [9] - **AdvisorShares Pure Cannabis ETF (YOLO)**: Lost 19.9% in 2024 but surged 79.3% recently, with top holdings including AdvisorShares Pure US Cannabis ETF (42.75%) and Village Farms International (16.04%) [10]

Core Insights - Cannabis stocks experienced a significant surge following Donald Trump's video promoting cannabis use for seniors and Medicaid coverage for CBD products [1][2] - The video, produced by the Commonwealth Project, highlights the potential benefits of hemp-derived CBD as a pain and stress reliever for seniors [1][2] - The cannabis industry is advocating for federal decriminalization to enhance research investment and broaden access to medical cannabis [6] Industry Impact - Stocks for major cannabis companies, including Canopy Growth, Tilray, and Cronos Group, saw substantial increases, with Tilray rising over 40% after the video release [2][6] - The AdvisorShares Cannabis ETF (MSOS) also experienced a notable rise on the same day [2] - The video emphasizes the need for educating healthcare providers and providing Medicare coverage for CBD, which could significantly impact the market [3] Regulatory Context - Under the Biden administration, there have been requests to the DEA to reclassify cannabis as a lower-risk substance, which is currently classified as Schedule I [4][5] - The Trump administration had previously been silent on cannabis decriminalization but indicated a willingness to consider reclassification [5] - Currently, 40 states permit medical cannabis use, while 24 states allow non-medical use, indicating a growing acceptance at the state level [5] Challenges and Opportunities - The Commonwealth Project notes that the current Schedule I classification complicates research and integration of cannabis into medical care, limiting access for seniors [7] - There is uncertainty regarding the stance of Terrance Cole, Trump's DEA administrator, on cannabis reclassification, as his focus has been on other priorities [7]

Industry Overview - The Canadian cannabis sector is a focal point for investors as it continues to evolve with expanding operations and long-term growth strategies [1][3] - The U.S. cannabis industry has surpassed $33 billion in annual sales, with projections exceeding $50 billion by 2030, indicating significant global opportunities for Canadian companies [1] - Recent developments in U.S. legalization discussions, including potential federal rescheduling of cannabis, could enhance banking access and reduce tax burdens, fostering optimism for both U.S. and Canadian firms [1][2] Company Summaries Cronos Group (CRON) - Cronos Group focuses on research, development, and global distribution, emphasizing branded products and international medical cannabis opportunities rather than a large U.S. dispensary network [4][7] - The company reported revenue of approximately CAD $33.5 million, a 20% year-over-year increase, but also a net loss of about CAD $38.5 million due to foreign-exchange headwinds and investment costs [7] - Cronos has improved gross margins and maintains a strong liquidity position, allowing for strategic flexibility and potential growth in global medical markets [7] SNDL Inc. (SNDL) - SNDL has established one of the largest retail footprints in Canada, operating over 180 retail locations under various banners, while also pursuing investments in the U.S. market [8][10] - The company reported net revenue of approximately CAD $244.8 million, with a gross profit increase of over 16% and positive operating income of around CAD $5 million for the first time in several years [10] - SNDL's strong cash position of over CAD $200 million and no debt on its balance sheet provide financial stability, while its strategy focuses on expanding its retail network and preparing for cross-border opportunities [10] Aurora Cannabis (ACB) - Aurora Cannabis emphasizes medical cannabis exports and global distribution, serving regulated medical markets in Europe and Australia, while shifting away from low-margin recreational cannabis [11][13] - The company reported total net revenue of about CAD $81 million, reflecting nearly 30% growth year-over-year, with medical cannabis sales increasing over 40% to more than CAD $61 million [13] - Aurora's adjusted gross margins improved to roughly 54%, showcasing higher profitability from its medical and international operations, despite challenges from regulatory shifts and competition [13] Investment Considerations - Investors should monitor the financial performance, operational strategies, and regulatory changes affecting Cronos Group, SNDL, and Aurora Cannabis, as each company presents unique opportunities and risks in the evolving cannabis landscape [14]

Core Insights - The prospects for marijuana legalization in the U.S. are facing setbacks due to opposition from influential legislators, negatively impacting cannabis stocks like Curaleaf [1][4] - President Trump is considering a measure to reschedule marijuana, which could lead to its de facto legalization at the federal level [2] - A group of nine Congress members, led by Congressman Pete Sessions, is actively opposing the rescheduling of marijuana, citing concerns over its impact on children and potential benefits to the marijuana industry [3][4] Industry Sentiment - The sentiment in the cannabis industry is currently negative, as evidenced by the decline in Curaleaf's stock price, which fell over 2% on a day when the S&P 500 only dropped 0.6% [1] - The ongoing debate and legislative pushback create uncertainty for cannabis operators, hindering their growth and access to financial services [4] Legislative Developments - The proposed rescheduling of marijuana by the DEA could eliminate its classification as a harmful drug, which is supported by public opinion but faces significant legislative opposition [2][3] - The letter sent to President Trump by Congress members highlights the political divide on marijuana legalization and the potential implications for the industry [3][4]